Editas Medicine is a clinical-stage gene-editing company building therapies with CRISPR/Cas technology to rewrite disease-causing DNA. Its programs have targeted inherited disorders, including ocular and hematologic indications where a one-time genetic correction could be transformative. The business model centers on proprietary editing platforms and pipeline assets rather than marketed drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 3.6 | — | -53.2 | — |
| Q3 2025 | 7.5 | — | -25.1 | — |
| Q4 2025 | 24.7 | — | -5.6 | — |
| Q1 2026 | 2.8 | — | -25 | — |
| Q2 2026 | 11.9 | 232.3% | -18.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Vital Farms, Inc. (VITL), Kochav Defense Acquisition Corp. (KCHV), ProCap Financial Inc (BRR), Waterstone Financial, Inc. (WSBF), Cohen Circle Acquisition Corp. II (CCII), Averin Capital Acquisition Corp. (ACAA)